Published Online:
December 7, 2011
This Cochrane Review is at the protocol stage and there is no abstract or plain language summary. The objectives for the review are as follows:
This review aims to provide an overview of evidence-based information and an analysis of the current data about ASCT in combination with high-dose chemotherapy for the treatment of CLL. We will analyse overall survival (OS) as primary endpoint and will also analyse progression-free survival (PFS), event-free survival (EFS), complete remission (CR), time interval between CLL diagnosis and ASCT, response rate, treatment-related mortality (TRM), time to next treatment, molecular remission (MR)/minimal residual disease (MRD), adverse events and quality of life.